Study finds that use of mHealth app could be useful in early detection of skin cancer but cautions that overdiagnosis is a possibility.
This article was originally published on Dermatology Times. It had been lightly edited.
As the use of artificial intelligence expands across the medical spectrum, researchers sought to determine the effect of a mobile phone app (mHealth) for identifying suspicious skin lesions on healthcare systems. Study authors found that use of an mHealth app for early detection of skin cancers was followed by an increase in the number of claims for premalignancies when matched with a control group.
In 2019, more than 2.2 million customers of a large Dutch insurance company were invited to use the mHealth (SkinVision) app free of charge. All insureds >18 who completed at least 1 app-based skin assessment of a suspicious lesion were included in the study. App users were matched to controls on a 1 to 3 ratio. Study authors were primarily interested in the frequency and type of dermatological claims between app users and controls.
Secondary objectives were to examine differences between therapeutic and diagnostic interventions for suspicious skin lesions, to determine the differences in direct healthcare costs, and to conduct a short-term, cross-sectional cost-effectiveness analysis.
The mHealth app used in the study uses a convolutional neural network (CNN) to identify skin lesions as high or low risk and send the information to the user. The recently validated CNN showed a sensitivity of 87–95% and a specificity of 70–78%.
Claims for benign skin tumors and nevi were almost 4 times higher among mHealth users (5.9%) compared to controls (1.7%) (OR 3.7 (95% CI 3.4–4.1)). App users also had a higher average annual cost for dermatological care (€64.97 vs. €43.09).
Study authors suggest that while use of an mHealth app for full body examinations is not recommended, an app could be helpful for examining high risk lesions. Users of the app had an increase in claims for (pre)malignancies so the authors suggest that use of the app could be a step toward identifying skin cancers. However, because the app detects all cutaneous (pre)malignancies, including melanomas, keratinocytic carcinomas, and actinic keratosis, which have different morbidities and mortalities, overdiagnosis is a risk of the app.
The incidence of false positives is another issue of the app. A diagnosis of skin cancer will likely cause anxiety for the user and lead to additional costs.
Limitations of the study included that mHealth app users tended to be younger, resulting in a large part of the older population for which the app is intended not being included. Also, study results were based on claims data, which most likely resulted in an underestimation of the impact of the app. In addition, users of the app are likely people who are more concerned about their skin, which could result in overdiagnosis.
Reference
Combining Surgical, Nonsurgical Approaches Holds Promise for Treating Facial Acne Scars
May 4th 2024According to a review, recent progress offers hope in the form of treatments, such as combination therapy that utilizes surgical and nonsurgical methods, for individuals with facial acne scars.
Read More
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Secukinumab Proves Successful in Treating Severe HS, Safety Persists at Week 52
April 11th 2024In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.
Read More
Delays in HS Diagnosis, Treatment Shed Light on Provider Education Gaps
April 5th 2024Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More